anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
In addition to describing sexual partner preferences, sexual self-labels in gay and bisexual (henceforth, sexual minority) men, such as top, bottom, and versatile, are associated with psychological characteristics (e.g., gendered personality traits). No research has explored the association between sexual self-labels and eating and body image disturbances in sexual minority men. Research in sexual minority men from China is particularly valuable and needed due to recent rises in rates of eating and body image disturbances and unique, minority-specific stressors experienced by Chinese sexual minority populations. We adopted an online, cross-sectional study in a sample of sexual minority men from China (N = 403; tops, n = 256, bottoms, n = 95, versatiles, n = 52). Bottoms reported higher thinness internalization, lower muscularity internalization, higher body fat dissatisfaction, and higher psychological distress than tops. Bottoms' weight bias internalization was higher than tops' and versatiles' reports and, compared to versatiles, bottoms also reported higher psychosocial impairment related to eating disorder psychopathology. Compared to versatiles, tops reported higher drive for muscularity and muscularity-oriented disordered eating. Adjusting for age, psychological distress, and psychosocial impairment, tops reported higher muscularity internalization than bottoms and higher drive for muscularity and muscularity-oriented disordered eating than both bottoms and versatiles. Findings suggested unique relations between sexual self-labels and eating and body image disturbances in Chinese sexual minority men. Replication and validation of the temporal order between sexual self-labels and eating and body image disturbances is needed, including assessment of social factors (e.g., femmephobia, minority stress) that may help explain the links between sexual self-labels and eating pathology.
Active intervention will last for 24 weeks and consists of 60-minute/session, which includes 10 minutes warm-up, 40 minutes of dancing and 10 minutes of cool down. In groups of 5, participants will practice the dance led by a physiotherapist once per week for the first 2 months and twice per week for 3rd to 6th month.
In accordance with the present invention, it has been discovered that a class of anti-dsDNA antibodies, e.g., mAb 3E10, binds membranes of fixed human renal tubular cells, penetrates live murine renal tubular cells in vivo, and localizes in the cell nucleus. mAb 3E10 binds both dsDNA and an extracellular matrix protein expressed in high endothelial venules (i.e., HP8/HEVIN). Previous studies showed both shared and distinct binding determinants in the variable heavy region of mAb 3E10 for DNA and HP8/HEVIN. To independently assess the requirement of HP8/HEVIN and DNA in cellular penetration, site directed mutants of mAb 3E10 VH and Vk were investigated for the ability to penetrate kidney cell lines. The results showed that residues required for binding DNA but not HP8/HEVIN were necessary for antibody penetration, indicating that cellular penetration required the presence of DNA or binding of antibody to a membrane determinant precisely resembling DNA. Antibody Fab penetrates cells, indicating that neither the Fc nor multivalent antibody binding are necessary for cellular penetration. Antibody synthesized in the cytoplasm as a result of deleting heavy and light chain signal peptides is not translocated to the nucleus, indicating the need for a membrane mediated pathway or for post-translational modifications of the antibody. The present invention demonstrates the usefulness of using molecular mutants and/or functional fragments thereof to study the cellular pathways of autoantibody penetration and nuclear localization.
BACKGROUND: Life with end-stage organ failure is accompanied by an accumulation of traumatic medical or surgical experiences. Despite recovery after solid organ transplantation (SOT), many children and adolescents develop post-traumatic stress symptoms (PTSS). PTSS remain underappreciated as a major comorbidity in SOT programs, despite their association with decreased quality of life.
METHODS: We conducted a retrospective, cross-sectional study of 86 pediatric SOT recipients (17 heart, 44 kidney, and 25 liver) to evaluate potential determinants of PTSS. Trauma symptoms were measured by the Child Trauma Screening Questionnaire (CTSQ). Demographic, baseline, and contemporaneous factors were tested for independent association with CTSQ scores.
RESULTS: The median post-transplant CTSQ score was 2 (IQR 1-4), and 22% were identified as high risk (score ≥5) for PTSD. Higher CTSQ scores were independently associated with the number of ICU days within the previous 12 months, the number of medications (complexity), and involvement with foster care in the primary model (R2 [adj.] = 0.26). The addition of the Family Impact Module improved the overall model (R2 [adj.] = 0.33), wherein higher family functioning was independently associated with lower CTSQ scores. An exploratory analysis of pre-transplant patients (n = 34) found a median pre-transplant CTSQ of 2 (IQR 1-6), suggesting that PTSS are onset before transplant and persist afterward.
CONCLUSIONS: PTSS are highly prevalent in the SOT population. Risk factors include recent adverse medical experiences and complexity, whereas family stability may be protective. Additional research is needed to improve early ascertainment and support for patients at high risk of developing PTSS throughout their transplant journey.
The controlled-tempo group followed a metronome for both eccentric and concentric phases of the leg press with the intention of maintaining a steady three-second concentric and three-second eccentric. This group completed 3 sets of 5 repetitions at 60% one-repetition maximum.
Parents assigned to the intervention arm will receive the Incredible Years® School Age Basic \& Advanced Parent Training Program. It consists of twelve (12) 2-hour online workshops led by a certified peer coach in the Incredible Years Parent Training Series.
The invented preparation consists of a basic material (1) containing active substances. The basic material (1) is provided with areas for release of active substances that are at least partially covered with a solid layer (2) capable of erosion. Ingredients formed by physiologically acceptable polymers having adhesive properties maintained even in the presence of liquids produce adhesion between the basic material (1) and said solid layer (2) capable of erosion. The basic material (1) is provided with at least one layer (2) capable of erosion having the form of a wedge. Said wedge-shaped layer (2) capable of erosion contains another active substance. The preparation can be used for controlled release of protective compositions for plants, fertilizers or antibacterial matters, particularly in flushing or washing devices.
The present invention relates to a method for preparing compound yin-nourishing capsules and granules by adding vegetoanimal medicinal material such as pure turtle carapaces, American ginseng, lilyturf roots, polygonati, xylitol, etc. in dendrobium candicum called as the 'leader of nine major China's fairy grasses'. The method comprises the following steps: preparing American ginseng powder for later use; boiling out the dendrobium, the lilyturf roots and the polygonati for twice, keeping juice and removing decoction dreg; charging the American ginseng powder and xylitol powder into concentrated extract, charging pure turtle carapace powder processed at ultralow temperature, palletizing and loading the final product into capsules or plastic-aluminum packaging bags. Thus, the compound yin-nourishing capsules and granules have the obvious effects of nourishing yin, moisturizing lungs and nourishing the stomach to promote production of body fluid, and the functions of enhancing immunity, resisting fatigue, controlling tumors, etc. As a result, the capsules and the granules are especially suitable for long-term use of patients with yin deficiency, dry cough, thirst, dry throats, dry eyes, blurry eyesight, feverish sensation in the palm and sole, toothache caused by fire deficiency, spiritlessness, impatience, soreness and weakness of waist and knees, and are also suitable for use in obvious symptoms of patients with diabetes, chronic tuberculosis or cancer after radiochemotherapy. Because the formula enhances the functions of nourishing yin, promoting the production of the body fluid and tonifying the kidney, the capsules and the granules are the best health care products for nourishing yin.
Flow disruption with Woven EndoBridge (WEB) is an innovative treatment that has been evaluated in several prospective and retrospective studies1-3. The efficacy and safety of this strategy has been largely proved, and nowadays, indications for WEBs are progressively enlarged. Appropriate sizing of the device is the key factor for treatment with a WEB. Undersized devices may lead to insufficient coverage of the aneurysm neck and inadequate filling of the volume of the sac, lowering the angiographic success. On the other hand, an excessively oversized WEB may cause an unwarranted protrusion into the parent vessel, increasing the risk of ischemic events. The conventional approach for WEB sizing is based on two-dimensional digital subtraction angiography (2D-DSA), adding 1mm to the average width (to assure good wall apposition), and subtracting 1mm to the average height of the aneurysm (to adjust for the longitudinal increase caused by the horizontal compression)4. However, the operator has to anticipate the behavior of the device, predicting tridimensional modifications of the WEB in relation to the volume and shape of the aneurysm dome and neck. Accordingly, appropriate WEB sizing could be difficult and may require experience. Data about software-based simulation to predict changes after device implantation have been reported for flow diversion and braided stents5-7. The Sim\&Size software (Sim\&Cure, Grabels, France) is able to perform virtual sizing before WEB deployment using pre or per-operative three-dimensional rotational angiography (3D-RA) acquisition. The virtual simulation helps to select the most appropriate size of the device, predicting the behavior of the WEB inside the aneurysm dome, and the surface of the WEB apposition, anticipating protrusion over the neck or inappropriate coverage of the ostium. This multicenter study aimed to explore if the use of the Sim\&Size software during endovascular embolization of intracranial aneurysms with WEB devices was associated with measurables procedural advantages compared with conventional sizing methods.

The primary investigated outcomes were 1) the median duration of the intervention; 2) the median radiation dose; 3) the need of corrective interventions; and 4) the number of WEBs opened but finally not deployed because of the inappropriate size of the device.

The secondary investigated endpoints were 1) the overall rate of complications (peri-procedural and long-term adverse events); 2) the morbidity rate (complications associated with permanent change of the clinical and neurological status of the patient); and 3) short-term (6 months) and long-term (12 months or more) aneurysm occlusion and WEB-shape change ("compaction") (decrease in height of the device or a deepening of the proximal and distal concave recesses during follow-up9 based on non-subtracted images)
For the patients Neoadjuvant FOLFOX chemotherapy is recommended for the resectable liver metastasis colorectal cancer. Neoadjuvant chemotherapy could suppress tumor, reduce metastasis, inhibit recurrence and improve long-term prognosis. Moreover, neoadjuvant chemotherapy could provide evidence about tumor response to drugs for the adjuvant chemotherapy. Furthermore, according to the biological behavior of tumors observed by neoadjuvant chemotherapy, unnecessarily excessive surgery could be avoided. However, some studies suggested that drug efficiency was consistent with resection rate. And FOLFOXIRI has been observed efficacy in the treatment of metastatic colorectal cancer with manageable toxicities. Therefore, we evaluate the efficacy and safety of neoadjuvant FOLFOXIRI chemotherapy in the patients with resectable liver metastasis of colorectal cancer to achieve higher resection rate and longer survival.

In this prospective study, 30 patients with resectable colorectal liver metastases were treated with neoadjuvant FOLFOXIRI chemotherapy. After 4 cycles of neoadjuvant chemotherapy, the liver metastases will be removed. If there are primary bowel lesions, they will be resected together. Safety profile was recorded based on NCI Common Terminology Criteria for Adverse Events version 4.0 (NCI-CTCAE v4.0). Objective response was evaluated by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1). Before treatment and after 4 cycles of neoadjuvant chemotherapy, we will evaluate tumor metabolic response via FDG-PET and monitor the dynamic changes of peripheral blood ctDNA.
The cortiscosteroid may be prednisone, butamethasone, dexamethasone, triamcinolone, methylprednisolone or prednisone. Compsns. of cyclogenzaprine with indomethacin, phenylbutazone, oxyphenbutazone or a cortiscosteroid are useful in the treatment of bursitis, synovitis, tenosynovitis, fibrositis, strains and sprains, muscle trauma, torticolis, rheumatism etc. Compsns. contng. cyclobenzaprine and chlordiazepoxide are useful in the treatment of psychophysical disorders e.g. migraine of tension. The compsns. have synergistic activity, so that the drugs may be administered in smaller doses than those normally used, giving rise to fewer side effects.
Several institutions have reported very low wear rates with crosslinked polyethylene based on early and midterm clinical data. However, since revisions associated with osteolysis typically occur after 10-year follow-up, the greatest benefits of the reduced wear associated with crosslinked polyethylene are expected to be reflected in lower revision rates for wear-related complications at long-term follow-up.

While crosslinking has proven to substantially reduce polyethylene wear during the first decade in vivo, characterizing the long-term clinical performance of Marathon polyethylene remains important because crosslinking is accompanied by a reduction in the ultimate tensile strength, fatigue strength, and elongation to failure of ultra high molecular weight polyethylene. As a consequence, concerns have been expressed about the potential for the liner fracture, in vivo polyethylene oxidation or accelerated wear at long-term follow-up, the effects of femoral head roughening over time and the bioreactivity of crosslinked polyethylene debris particles. Ultimately, the best way to address these concerns is in the context of well-controlled, long-term clinical outcome studies. This study will evaluate outcome at a minimum of 14-years after surgery among the same group of patients whose outcome was previously reported at 10-year follow-up. As part of our efforts to follow patients throughout their lives to obtain long-term outcome data, we will continue to obtain routine follow-up every 5 years from the date of the patient's primary total hip arthroplasty for the duration of the patient's life or until revision of the polyethylene liner (estimated to be 25 years). Because we anticipate that the reduced incidence of wear and osteolysis will result in a lower incidence of revision surgery among the patients randomized to Marathon liners, implant revision for reasons related to wear will be our primary outcome measure at long-term follow-up.
BACKGROUND: Vertical sleeve gastrectomy (SGx) is a type of bariatric surgery to treat morbid obesity and metabolic dysfunction-associated steatotic liver disease (MASLD). The molecular mechanisms of SGx to improve MASLD are unclear, but increased bile acids (BAs) and FGF19 (mouse FGF15) were observed. FGF15/19 is expressed in the ileum in response to BAs and is critical in not only suppressing BA synthesis in the liver but also promoting energy expenditure. We hypothesized the reduction of obesity and resolution of MASLD by SGx may be mediated by FGF15/19.
METHODS: First, we conducted hepatic gene expression analysis in obese patients undergoing SGx, with the results showing increased expression of FGF19 in obese patients' livers. Next, we used wild-type and intestine-specific Fgf15 knockout mice (Fgf15ile-/-) to determine the effects of FGF15 deficiency on improving the metabolic effects.
RESULTS: SGx improved metabolic endpoints in both genotypes, evidenced by decreased obesity, improved glucose tolerance, and reduced MASLD progression. However, Fgf15ile-/- mice showed better improvement compared to wild-type mice after SGx, suggesting that other mediators than FGF15 are also responsible for the beneficial effects of FGF15 deficiency. Further gene expression analysis in brown adipose tissue suggests increased thermogenesis.
CONCLUSIONS: FGF15 deficiency, the larger BA pool and higher levels of secondary BAs may increase energy expenditure in extrahepatic tissues, which may be responsible for improved metabolic functions following SGx.
The specific gamma ray constant for thallium Tl-201 is 4.64 R/mCi-hr at 1 cm. The first half-value thickness of lead (Pb) is 0.0006 cm. A range of values for the radiation emitted by this radionuclide with the corresponding exposure rate at 1 cm that results from interposition of various thicknesses of lead is shown in Table 4. For example, the use of 0.21 cm of lead will decrease the external radiation exposure by a factor of about 1,000.

Table 4. Radiation Attenuation by Lead Shielding

Data supplied by Oak Ridge Associated Universities, Radiopharmaceutical Internal Dose Information Center, Oak Ridge, TN, 1994. Includes 10 keV x-rays 4. 

To correct for physical decay of the radionuclide, the fractions that remain at selected intervals after calibration time are shown in Table 5.

Table 5. Thallous Chloride Tl 201 Decay Chart; Half-Life 72.9 Hours

* Calibration Time
BACKGROUND: Enteral nutrition intolerance (ENI) is often defined as one or more gastrointestinal (GI) symptoms related to enteral nutrition (EN) and may have significant impact on patient outcomes. There are multiple strategies to help manage ENI, such as changing the EN formula. The objective of this practice survey was to understand prevalence of ENI, management of ENI symptoms, and EN formula features considered when changing formulas to manage ENI.
METHODS: Canadian clinical dietitians working across care settings (n = 4827) were invited to complete a 28-question online survey if involved in the management of adult and/or pediatric patients receiving EN.
RESULTS: Five hundred seventeen surveys were analyzed. Significantly more dietitians in adult vs pediatric settings (83.4% and 59.1%, respectively; P = 0.0012), reported ENI in <40% of patients. Assessing medications, elevating the head of the bed, and changing EN infusion rate, volume, or feeding regimen were the highest-ranked strategies to manage ENI symptoms. Most (>90%) respondents change the EN formula <50% of the time to manage ENI. Dietitians consider caloric density and protein form as the most important EN features to manage upper-GI symptoms vs fiber source, osmolality, and form of protein to manage lower-GI symptoms. EN with real-food ingredients was ranked higher in importance for managing upper- and lower-GI symptoms by dietitians in pediatric vs adult settings.
CONCLUSION: To manage ENI symptoms, dietitians consider multiple strategies before deciding to change the EN formula. When a formula change is indicated, dietitians consider different EN features for the management of upper- and lower-GI symptoms.
Every patient will receive anti-PD-1 antibody (200 mg intravenous drip every 3 weeks) and XELOX regimen chemotherapy (Oxaliplatin 130 mg/m2, intravenous drip, d1; Capecitabine 1000mg/ kg, twice a day, orally, d1-14;every 21 days). Anti-PD-1 antibody will be administered until the disease progresses or lasts for two years. XELOX will be administered 6-8cycles，followed by capecitabine monotherapy, the course of treatment is determined by the investigators according to clinical practice.
Both studies were conducted previously and were randomized, double-blind and placebo-controlled. They followed very similar protocols, were of nearly identical design, had common inclusion and exclusion criteria. Both studies achieved statistical significance for ammonium succinate-based dietary supplement on most of pre-specified endpoints of Greene Climacteric Scale symptoms severity reduction at week 12. Nevertheless, some minor variation in the patient population, both within the studies (e.g., between different centres, as well as seasonal variability) and between the studies can be expected.

Naturally occuring estrogen deficiency over the course of the menopausal transition and postmenopause causes hot flushes and other psychosomatic and vasomotor symptoms. Menopausal hormone therapy is a method of choice, however in many cases it is contraindicated or unacceptable for other reasons. Many alternatives exist, generally acting via estrogen receptors (ER). The dietary supplement tested in the aforementioned studies contains ammonium succinate, which does not bind to ER, instead acting by supporting the Krebs cycle. It does not have phytoestrogenic ingredients.
Participants in the acupuncture group will receive a standardized Traditional Chinese Medicine (TCM) point prescription. Acupuncture will be administered 2 times per week for 5 weeks for a total of 10 treatments.
FIELD: bioinorganic chemistry, pharmacology, experimental microbiology. SUBSTANCE: method of treatment and disinfection of biological material involves addition of enzyme solution, incubation, addition of Lugol's aqueous solution and repeated incubation. Solution of FeCl 3  can be added to biological material additionally. Method provides the possibility to attain bactericidal effect but to sorb and remove extracellular microorganisms, antigens, bacterial toxins and products of decomposition of damaged infected tissues from body. Method ensures to avoid immunological complications also. EFFECT: enhanced effectiveness of method, broadened effectiveness of enzymes action. 2 cl, 2 tbl
PURPOSE: To use, for cosmetic and dermatological purpose, a spin trap such as 2,2,6,6-tetramethylpiperidine-1-oxide employed as an electron paramagnetic resonance measurement probe, for light-protective, anti-aging and anti-acne treatments. CONSTITUTION: This composition comprises a spin trap employed as an electron paramagnetic resonance measurement probe and a cosmetically and dermatologically acceptable medium, being encapsulated in microspheres. The spin trap is e.g. 2,2,6,6-tetrametylpiperidine-1-oxide,4- hydroxytetramethylpiperidine-1-oxide, N-t-butyl-α-phenylnitron. The above microspheres are pref. lipid vesicles which are capable of diffusing into the deep layers of the skin. In particular, the microspheres pref. stand in gel form at room temperature, consisting of e.g. triglycedryl cetyl ether/cholesterol/casein lipoamino acid.
Methods for discovery of enzyme ligands and inhibitors are disclosed. The methods comprise the creation and testing of combinatorial libraries comprising an active site-targeted component, a linker component and a peripheral site-targeted component. The methods also comprise a novel assay for determining whether a compound is a ligand of an enzyme. The assay evaluates whether the compound can inhibit the binding of a known ligand of the active site of the enzyme to a mutant of the enzyme that can bind the enzyme substrate but cannot catalyze an enzymatic reaction with the substrate.  Various ligands and inhibitors of protein tyrosine phosphatase 1B (PTP1B) are also disclosed. These ligands and inhibitors were discovered using the above methods. One particular inhibitor discovered using the invention methods has the highest specificity and affinity of any PTP1B inhibitor discovered to date.